Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma

Clinical trial NCT01351038 · TERMINATED

Trial details

NCT number: NCT01351038
Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

KRAS Wild Type Resectable Type II Gastric Adenocarcinoma

Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.